SPARCL1

Across TCGA pan-cancer cohorts, SPARCL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPARCL1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPARCL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPARCL1 expression acts as an unfavorable survival marker.

LUAD, UCEC, and GBM are the cancer types where SPARCL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.244	0.781	.001	38	view →
UCEC	OS	Tertile	II,III,IV	0.553	1.000	.026	8	view →
GBM	DFS	Median	All	0.261	0.489	.016	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPARCL1–LUAD (OS)

Open the LUAD breakdown →